Seres Therapeutics, Inc. (NASDAQ:MCRB) Fails To Meet SER-109 Phase 2 ECOSPOR Clinical Trial Primary Endpoint

Seres Therapeutics, Inc. (NASDAQ:MCRB) has revealed on Friday in the interim eight-week results of the SER-109 Phase 2 ECOSPOR clinical trial for the prevention of multiply recurrent Clostridium Difficile Infection (CDI) that it did not attain the primary endpoint of minimizing the CDI recurrence relative risk at up to eight weeks. How Seres Therapeutics Plans […]